| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 112,949 | 335,816 | ||
| Marketable securities (note 4) | 392,733 | 329,629 | ||
| Contract assets | 0 | 0 | ||
| Accounts receivable | - | 40,000 | ||
| Prepaid expenses and other current assets | 22,616 | 22,882 | ||
| Total current assets | 528,298 | 728,327 | ||
| Marketable securities, non-current (note 4) | 473,055 | 297,629 | ||
| Total property and equipment | 67,483 | - | ||
| Less accumulated depreciation | 22,355 | - | ||
| Property and equipment, net (note 6) | 45,128 | 48,572 | ||
| Right-of-use assets, operating leases | 42,947 | 46,045 | ||
| Other non-current assets | 6,828 | 4,675 | ||
| Restricted cash | 5,788 | 5,820 | ||
| Total assets | 1,102,044 | 1,131,068 | ||
| Accounts payable | 5,506 | 5,781 | ||
| Accrued expenses (note 8) | 28,639 | 27,976 | ||
| Deferred revenue | 23,279 | 40,000 | ||
| Operating lease liabilities | 11,853 | 11,766 | ||
| Finance lease liabilities | 1,890 | 1,900 | ||
| Other current liabilities | 408 | 117 | ||
| Total current liabilities | 71,575 | 87,540 | ||
| Deferred revenue, net of current portion | 13,957 | - | ||
| Operating lease liabilities, net of current portion | 68,450 | 69,835 | ||
| Finance lease liabilities, net of current portion | 1,804 | 2,213 | ||
| Total liabilities | 155,786 | 159,588 | ||
| Common stock, 0.0001 par value 150,000,000 shares authorized at september 30, 2025 and december 31, 2024, 71,741,174 and 64,890,193 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 7 | 7 | ||
| Additional paid-in capital | 1,923,730 | 1,867,999 | ||
| Accumulated deficit | -978,980 | -896,805 | ||
| Accumulated other comprehensive loss | 1,501 | 279 | ||
| Total stockholders equity | 946,258 | 971,480 | ||
| Total liabilities and stockholders equity | 1,102,044 | 1,131,068 | ||
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR)